

Stefano Bonora

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6002286/stefano-bonora-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

247
papers

4,137
citations

33
h-index

51
g-index

261
ext. papers

4,721
ext. citations

5.4
avg, IF

5
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 247 | Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV.. <i>AIDS and Behavior</i> , 2022 , 1 | 4.3 | |
| 246 | Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition.. <i>Viruses</i> , 2022 , 14, | 6.2 | 1 |
| 245 | Trichinella britovi outbreak in Piedmont, North-West Italy, 2019-2020: Clinical and epidemiological insights in the one health perspective.. <i>Travel Medicine and Infectious Disease</i> , 2022 , 47, 102308 | 8.4 | 3 |
| 244 | Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases.. <i>Frontiers in Microbiology</i> , 2022 , 13, 829393 | 5.7 | |
| 243 | Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers.. <i>Vaccines</i> , 2021 , 9, | 5.3 | 2 |
| 242 | On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. <i>Frontiers in Microbiology</i> , 2021 , 12, 646679 | 5.7 | 6 |
| 241 | Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106297 | 14.3 | 0 |
| 240 | The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 665-676 | 5.5 | 2 |
| 239 | The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab217 | 1 | 16 |
| 238 | Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4432-4438 | 3.8 | 1 |
| 237 | Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. <i>Diagnostics</i> , 2021 , 11, | 3.8 | 3 |
| 236 | Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. <i>Lancet Infectious Diseases</i> , 2021 , 21, 914-915 | 25.5 | 5 |
| 235 | Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 103-109 | 6.2 | 6 |
| 234 | Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 443-456 | 5.5 | 0 |
| 233 | Co-infection with other respiratory pathogens in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 297-298 | 9.5 | 23 |
| 232 | Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. <i>Viruses</i> , 2021 , 13, | 6.2 | 22 |
| 231 | Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 84, 290-294 | 3.1 | 0 |

| | | | |
|-----|--|------|----|
| 230 | Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalICONA foundation cohorts. <i>Digestive and Liver Disease</i> , 2020 , 52, 447-451 | 3.3 | 1 |
| 229 | Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2020 , 14, | 5.2 | 2 |
| 228 | Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. <i>Aids</i> , 2020 , 34, 373-380 | 3.5 | 7 |
| 227 | Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 628-639 | 5.1 | 5 |
| 226 | Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. <i>Aids</i> , 2020 , 34, 1899-1906 | 3.5 | 3 |
| 225 | Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. <i>Thrombosis Research</i> , 2020 , 196, 432-434 | 8.2 | 10 |
| 224 | Good times, bad times: A diary of a physician in the COVID-19 era. <i>European Journal of Internal Medicine</i> , 2020 , 77, 132-133 | 3.9 | |
| 223 | A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. <i>Journal of NeuroVirology</i> , 2020 , 26, 642-651 | 3.9 | 8 |
| 222 | Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , | 5.9 | 2 |
| 221 | Cerebral white matter Hyperintensities in HIV-positive patients. <i>Brain Imaging and Behavior</i> , 2020 , 14, 10-18 | 4.1 | 5 |
| 220 | Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. <i>Pharmacogenomics Journal</i> , 2020 , 20, 202-212 | 3.5 | 3 |
| 219 | Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. <i>Antiviral Therapy</i> , 2020 , 25, 327-333 | 1.6 | 1 |
| 218 | Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3295-3304 | 5.1 | 12 |
| 217 | Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25227 | 5.4 | 24 |
| 216 | The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. <i>Journal of NeuroVirology</i> , 2019 , 25, 887-892 | 3.9 | 2 |
| 215 | Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , 2019 , 116, 23-28 | 14.5 | 3 |
| 214 | In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 321-326 | 1.9 | 3 |
| 213 | Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. <i>Aids</i> , 2019 , 33, 1256-1260 | 3.5 | 8 |

| | | | |
|-----|--|------|----|
| 212 | HIV-1 detection in the olfactory mucosa of HIV-1-infected participants. <i>Aids</i> , 2019 , 33, 665-674 | 3.5 | 2 |
| 211 | Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 94, 202-204 | 2.9 | 1 |
| 210 | SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1035-1043 | 5.1 | 15 |
| 209 | Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-128 | 5.38 | 5 |
| 208 | Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?. <i>Pharmacogenomics Journal</i> , 2019 , 19, 65-71 | 3.5 | 3 |
| 207 | Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Name for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019 , 20, 99-109 | 2.7 | 11 |
| 206 | The clinical pharmacology of integrase inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 31-44 | 5.8 | 5 |
| 205 | Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 546-548 | 5.1 | 2 |
| 204 | The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. <i>Antiviral Therapy</i> , 2018 , 23, 451-456 | 1.6 | 5 |
| 203 | Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1380-1383 | 3.8 | 2 |
| 202 | CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. <i>Current HIV/AIDS Reports</i> , 2018 , 15, 84-91 | 5.9 | 13 |
| 201 | Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 59-82 | 5.5 | 28 |
| 200 | Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 826-827 | 5.1 | 16 |
| 199 | Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600 | 13.4 | 23 |
| 198 | Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). <i>Journal of NeuroVirology</i> , 2018 , 24, 679-694 | 3.9 | 2 |
| 197 | Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. <i>Atherosclerosis</i> , 2018 , 274, 218-226 | 3.1 | 17 |
| 196 | Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1550-1556 | 2.9 | 6 |
| 195 | Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy113 | 1 | 34 |

| | | | |
|-----|---|------|----|
| 194 | Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. <i>HIV Medicine</i> , 2018 , 19, 455 | 2.7 | 13 |
| 193 | Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62, | 5.9 | 2 |
| 192 | First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018 , 19, 475 | 2.7 | 10 |
| 191 | Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1146-1148 | 3.8 | 3 |
| 190 | Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. <i>Journal of Clinical Virology</i> , 2017 , 87, 30-36 | 14.5 | 5 |
| 189 | Treating HIV Infection in the Central Nervous System. <i>Drugs</i> , 2017 , 77, 145-157 | 12.1 | 9 |
| 188 | UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 138, 223-230 | 3.5 | 34 |
| 187 | Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741 | 3.3 | 14 |
| 186 | Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤ 50 copies/mL. <i>Infection</i> , 2017 , 45, 521-528 | 5.8 | 9 |
| 185 | Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. <i>Journal of Cardiovascular Medicine</i> , 2017 , 18, 539-544 | 1.9 | 15 |
| 184 | Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017 , 18, 865-880 | 2.6 | 5 |
| 183 | Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1741-1744 | 5.1 | 14 |
| 182 | PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017 , 12, e0181433 | 3.7 | 5 |
| 181 | Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. <i>PLoS ONE</i> , 2017 , 12, e0189425 | 3.7 | 3 |
| 180 | Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3163-3166 | 5.1 | 5 |
| 179 | Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. <i>Antiviral Therapy</i> , 2017 , 22, 539-543 | 1.6 | 9 |
| 178 | Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy?. <i>Journal of NeuroVirology</i> , 2017 , 23, 763-767 | 3.9 | 4 |
| 177 | Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. <i>Journal of NeuroImmune Pharmacology</i> , 2017 , 12, 187-193 | 6.9 | 10 |

| | | | |
|-----|---|-----|----|
| 176 | Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 355-369 | 6.2 | 19 |
| 175 | High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. <i>Current HIV Research</i> , 2017 , 15, 258-265 | 1.3 | 1 |
| 174 | Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 812-815 | 5.1 | 6 |
| 173 | Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 855-865 | 5.1 | 7 |
| 172 | Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting. <i>AIDS Reviews</i> , 2017 , 19, 24-34 | 1.5 | 4 |
| 171 | Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , 2016 , 16, 514-518 | 3.5 | 18 |
| 170 | HCV NS3 naturally occurring variants in HIV/HCV coinfecting DAA-naïve patients: consideration for HCV genotyping resistance testing. <i>Infection</i> , 2016 , 44, 789-792 | 5.8 | 3 |
| 169 | Zika virus infection in two travelers returning from an epidemic area to Italy, 2016: Algorithm for diagnosis and recommendations. <i>Travel Medicine and Infectious Disease</i> , 2016 , 14, 506-508 | 8.4 | 6 |
| 168 | From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005 | 3.3 | 12 |
| 167 | Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016 , 30, 915-20 | 3.5 | 11 |
| 166 | Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016 , 497, 287-92 | 6.5 | 9 |
| 165 | Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2016 , 37, 3600-3609 | 8.5 | 29 |
| 164 | HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. <i>Progress in Cardiovascular Diseases</i> , 2016 , 58, 565-76 | 8.5 | 30 |
| 163 | Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1330-40 | 5.1 | 8 |
| 162 | Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 409-19 | 4 | 8 |
| 161 | Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. <i>Journal of NeuroVirology</i> , 2016 , 22, 88-92 | 3.9 | 31 |
| 160 | Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016 , 11, e0160761 | 3.7 | 4 |
| 159 | Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. <i>Current HIV Research</i> , 2016 , 14, 54-60 | 1.3 | 7 |

| | | | |
|-----|--|------|-----|
| 158 | Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. <i>Antiviral Therapy</i> , 2016 , 21, 633-635 | 1.6 | 8 |
| 157 | Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 409-11 | 1.6 | 15 |
| 156 | Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 117-23 | 14.3 | 21 |
| 155 | Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 750-4 | 2.2 | 1 |
| 154 | Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain. <i>International Journal of Clinical Pharmacy</i> , 2016 , 38, 749-51 | 2.3 | 4 |
| 153 | Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1167-76 | 5.5 | 7 |
| 152 | Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 801-8 | 3.8 | 12 |
| 151 | High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. <i>Atherosclerosis</i> , 2015 , 240, 197-204 | 3.1 | 61 |
| 150 | A LC-MS method to quantify tenofovir urinary concentrations in treated patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 114, 8-11 | 3.5 | 17 |
| 149 | Heart failure in patients with human immunodeficiency virus: a review of the literature. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16, 383-9 | 1.9 | 13 |
| 148 | Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naïve adults. <i>Aids</i> , 2015 , 29, 193-200 | 3.5 | 9 |
| 147 | A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2572-5 | 5.1 | 18 |
| 146 | Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3074-9 | 5.1 | 10 |
| 145 | Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3096-9 | 5.1 | 14 |
| 144 | Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. <i>Archives of Virology</i> , 2015 , 160, 2881-5 | 2.6 | 10 |
| 143 | HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 999-1008 | 1.6 | 15 |
| 142 | Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. <i>Clinical Infectious Diseases</i> , 2015 , 60, 311-7 | 11.6 | 41 |
| 141 | Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2015 , 211, 178-86 | 7 | 114 |

| | | | |
|-----|--|------|----|
| 140 | Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS. <i>Antiviral Therapy</i> , 2015 , 20, 357-9 | 1.6 | 4 |
| 139 | Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 695-6 | 3.2 | 2 |
| 138 | A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16, 839-43 | 1.9 | 19 |
| 137 | Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015 , 10, e0124252 | 3.7 | 5 |
| 136 | Cardiovascular disease in HIV patients: from bench to bedside and backwards. <i>Open Heart</i> , 2015 , 2, e000174 | 1.74 | 56 |
| 135 | Acute HIV infection: improved algorithms for HIV testing. <i>Journal of Clinical Virology</i> , 2015 , 63, 51-2 | 14.5 | 4 |
| 134 | An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. <i>New Microbiologica</i> , 2015 , 38, 443-90 | 1.1 | 6 |
| 133 | A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]. <i>Infezioni in Medicina</i> , 2015 , 23, 367-9 | 3.6 | 3 |
| 132 | Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1911-5 | 5.1 | 9 |
| 131 | Local and global spatio-temporal dynamics of HIV-1 subtype F1. <i>Journal of Medical Virology</i> , 2014 , 86, 186-92 | 19.7 | 7 |
| 130 | A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 94, 65-70 | 3.5 | 8 |
| 129 | Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4042-7 | 5.9 | 12 |
| 128 | Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1436-9 | 5.1 | 4 |
| 127 | Prevalence and predictors of blood-brain barrier damage in the HAART era. <i>Journal of NeuroVirology</i> , 2014 , 20, 521-5 | 3.9 | 15 |
| 126 | High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 241-5 | 5.1 | 24 |
| 125 | Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy. <i>BMC Infectious Diseases</i> , 2014 , 14, 398 | 4 | 10 |
| 124 | The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014 , 11, 49 | 3.6 | 32 |
| 123 | Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3061-6 | 5.1 | 34 |

| | | | |
|-----|--|------|----|
| 122 | Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome. <i>BMC Anesthesiology</i> , 2014 , 14, 37 | 2.4 | 25 |
| 121 | Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. <i>Thrombosis Research</i> , 2014 , 134, 558-64 | 8.2 | 36 |
| 120 | Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Research</i> , 2014 , 108, 44-7 | 10.8 | 6 |
| 119 | Cerebrospinal fluid biomarkers in patients with plasma HIV RNA below 20 copies/mL. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19719 | 5.4 | 3 |
| 118 | An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19771 | 5.4 | 1 |
| 117 | Durability of lopinavir/ritonavir dual-therapies in individuals with viral load . <i>Journal of the International AIDS Society</i> , 2014 , 17, 19799 | 5.4 | 1 |
| 116 | Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19571 | 5.4 | 1 |
| 115 | Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 891-906 | 6.2 | 51 |
| 114 | Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2586-8 | 5.1 | 1 |
| 113 | Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. <i>Pharmacogenomics</i> , 2014 , 15, 1281-6 | 2.6 | 6 |
| 112 | No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. <i>Aids</i> , 2014 , 28, 1993-5 | 3.5 | 1 |
| 111 | Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 835-6 | 1.6 | 3 |
| 110 | Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients. <i>Current HIV Research</i> , 2014 , 12, 339-46 | 1.3 | 7 |
| 109 | Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness. <i>New Microbiologica</i> , 2014 , 37, 285-306 | 1.1 | |
| 108 | Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1677-8 | 11.6 | 2 |
| 107 | Evaluation of a rapid antigen and antibody combination test in acute HIV infection. <i>Journal of Clinical Virology</i> , 2013 , 57, 84-7 | 14.5 | 37 |
| 106 | Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, e118-9 | 3.1 | 2 |
| 105 | Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1686-8 | 5.1 | 10 |

| | | | |
|-----|---|------|----|
| 104 | Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 907-10 | 5.1 | 18 |
| 103 | Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 482-4 | 5.1 | 3 |
| 102 | Experimental evaluation of a new system for laser tissue welding applied on damaged lungs. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013 , 16, 577-82 | 1.8 | 4 |
| 101 | Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1840-5 | 5.9 | 31 |
| 100 | Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. <i>European Heart Journal</i> , 2013 , 34, 1432-6 | 9.5 | 94 |
| 99 | Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. <i>PLoS ONE</i> , 2013 , 8, e80157 | 3.7 | 31 |
| 98 | Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 66, 376-80 | 3.5 | 24 |
| 97 | Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 134-40 | 3.8 | 29 |
| 96 | Inpatient and outpatient pharmacokinetic variability of raltegravir in the clinical setting. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 232-5 | 3.2 | 29 |
| 95 | Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 722-8 | 3.2 | 30 |
| 94 | Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anemia in patients receiving standard anti-HCV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 165-70 | 3.2 | 37 |
| 93 | Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2236-42 | 5.1 | 16 |
| 92 | Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. <i>Aids</i> , 2012 , 26, 1529-33 | 3.5 | 33 |
| 91 | Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. <i>Aids</i> , 2011 , 25, 1437-9 | 3.5 | 19 |
| 90 | Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART. <i>Antiviral Therapy</i> , 2011 , 16, 797-803 | 1.6 | 7 |
| 89 | Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. <i>Antiviral Therapy</i> , 2011 , 16, 499-504 | 1.6 | 9 |
| 88 | No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 391-8 | 19.7 | 1 |
| 87 | Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011 , 54, 2278-9 | 11.2 | 25 |

| | | | |
|----|--|------|-----|
| 86 | A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 779-88 | 3.5 | 55 |
| 85 | Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 885-9 | 5.1 | 4 |
| 84 | Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 192-200 | 5.1 | 14 |
| 83 | Genetic variants of ABCB1, a novel tenofovir transporter, are associated with kidney tubular dysfunction. <i>Journal of Infectious Diseases</i> , 2011 , 204, 145-53 | 7 | 92 |
| 82 | Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1932-4 | 5.1 | 7 |
| 81 | Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2976-8 | 5.9 | 53 |
| 80 | Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 759-65 | 1.9 | 38 |
| 79 | Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. <i>PLoS ONE</i> , 2010 , 5, e13540 | 3.7 | 73 |
| 78 | Raltegravir penetration in seminal plasma of healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2744-5 | 5.9 | 13 |
| 77 | Is peritoneal fluid a sanctuary site for HIV?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2052-3 | 5.1 | 1 |
| 76 | Raltegravir: is a 400 mg once-daily dose enough?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 595-7 | 5.1 | 6 |
| 75 | Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5242-50 | 5.9 | 63 |
| 74 | Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. <i>Aids</i> , 2010 , 24, 931-2 | 3.5 | 11 |
| 73 | Phase control of a path-entangled photon state by a deformable membrane mirror. <i>Journal of the Optical Society of America B: Optical Physics</i> , 2010 , 27, A175 | 1.7 | 6 |
| 72 | Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients. <i>Journal of Clinical Virology</i> , 2010 , 47, 8-12 | 14.5 | 15 |
| 71 | A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 86-92 | 3.2 | 19 |
| 70 | Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010 , 24, 1064-6 | 3.5 | 103 |
| 69 | Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. <i>Journal of Medical Virology</i> , 2010 , 82, 1996-2003 | 19.7 | 5 |

| | | | |
|----|---|------|----|
| 68 | HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 52, 774-80 | 3.5 | 62 |
| 67 | Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 874-5 | 5.1 | 9 |
| 66 | Molecular typing of <i>Mycobacterium bovis</i> strains isolated in Italy from 2000 to 2006 and evaluation of variable-number tandem repeats for geographically optimized genotyping. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 636-44 | 9.7 | 85 |
| 65 | Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 575-8 | 5.1 | 9 |
| 64 | Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 2816-23 | 5.9 | 15 |
| 63 | Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1636-7 | 11.6 | 2 |
| 62 | Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. <i>Journal of Medical Virology</i> , 2009 , 81, 400-5 | 19.7 | 49 |
| 61 | Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients. <i>Current HIV Research</i> , 2009 , 7, 425-33 | 1.3 | 1 |
| 60 | Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 431-2 | 3.1 | 17 |
| 59 | Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?. <i>Clinical Drug Investigation</i> , 2008 , 28, 305-11 | 3.2 | 0 |
| 58 | A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. <i>Journal of Chromatographic Science</i> , 2008 , 46, 524-8 | 1.4 | 36 |
| 57 | Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. <i>Clinical Infectious Diseases</i> , 2008 , 46, 146-7 | 11.6 | 29 |
| 56 | Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1066-71 | 5.9 | 15 |
| 55 | A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1356-64 | 5.1 | 9 |
| 54 | Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 384-7 | 5.1 | 6 |
| 53 | Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1222-5 | 11.6 | 73 |
| 52 | Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1188-90 | 5.1 | 2 |
| 51 | Even-order aberration cancellation in quantum interferometry. <i>Physical Review Letters</i> , 2008 , 101, 233603 | 3.4 | 24 |

| | | | |
|----|--|------|----|
| 50 | A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 90-4 | 3.2 | 9 |
| 49 | An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 662-9 | 3.2 | 99 |
| 48 | Interactions between antiretroviral agents and those used to treat tuberculosis. <i>Current Opinion in HIV and AIDS</i> , 2008 , 3, 306-12 | 4.2 | 12 |
| 47 | Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. <i>Journal of Infection</i> , 2008 , 57, 78-81 | 18.9 | 12 |
| 46 | A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 848, 374-8 | 3.2 | 22 |
| 45 | HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 859, 234-40 | 3.2 | 77 |
| 44 | Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 565-8 | 5.1 | 11 |
| 43 | Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1654-5 | 11.6 | 9 |
| 42 | Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 180-5 | 3.1 | 29 |
| 41 | Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 483-5 | 5.1 | 1 |
| 40 | Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 714-22 | 5.1 | 68 |
| 39 | Enfuvirtide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. <i>Aids</i> , 2006 , 20, 297-9 | 3.5 | 23 |
| 38 | An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 110-5 | 3.2 | 11 |
| 37 | Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. <i>Aids</i> , 2006 , 20, 1977-9 | 3.5 | 23 |
| 36 | Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 835, 127-30 | 3.2 | 46 |
| 35 | Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy. <i>Expert Opinion on Drug Safety</i> , 2005 , 4, 821-36 | 4.1 | 18 |
| 34 | Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. <i>AIDS Reviews</i> , 2005 , 7, 161-7 | 1.5 | 3 |
| 33 | Which agents should we use for the treatment of multidrug-resistant <i>Mycobacterium tuberculosis</i> ?. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 593-602 | 5.1 | 88 |

| | | | |
|----|--|------|----|
| 32 | The relationship between nevirapine plasma concentrations and abnormal liver function tests. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 716-22 | 1.6 | 56 |
| 31 | Intrapulmonary concentrations of cefepime. <i>Critical Care Medicine</i> , 2004 , 32, 1238; author reply 1238-9 | 1.4 | |
| 30 | Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine. <i>Aids</i> , 2004 , 18, 577-8 | 3.5 | 7 |
| 29 | Lopinavir protein binding in vivo through the 12-hour dosing interval. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 35-9 | 3.2 | 46 |
| 28 | Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 941-2 | 1.6 | 5 |
| 27 | HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 439-47 | 3.1 | 18 |
| 26 | Treating advanced HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 34, 344-51 | 3.1 | 5 |
| 25 | Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis. <i>Clinical Infectious Diseases</i> , 2003 , 36, 1492-5 | 11.6 | 17 |
| 24 | Healthy ranges for alanine aminotransferase levels. <i>Annals of Internal Medicine</i> , 2003 , 138, 156-7; author reply 156-7 | 8 | 3 |
| 23 | Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. <i>Aids</i> , 2003 , 17, 1107-8 | 3.5 | 24 |
| 22 | The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 262-8 | 3.8 | 10 |
| 21 | Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3684-5 | 5.9 | 2 |
| 20 | Pharmacokinetics of saquinavir co-administered with cimetidine. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 50, 1081-4 | 5.1 | 18 |
| 19 | Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 859-60 | 4 | 14 |
| 18 | Simultaneous determination of rifampicin and efavirenz in plasma. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 670-4 | 3.2 | 11 |
| 17 | Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. <i>Aids</i> , 2002 , 16, 2081-3 | 3.5 | 49 |
| 16 | Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 574-6 | 3.2 | 3 |
| 15 | Rising temperature and the malaria epidemic in Burundi. <i>Trends in Parasitology</i> , 2001 , 17, 572-3 | 6.4 | 14 |

| | | | |
|----|--|------|-----|
| 14 | Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the hsp65 gene. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 2799-806 | 9.7 | 118 |
| 13 | Mycobacterium tuberculosis transmission and HIV status. <i>Lancet, The</i> , 2000 , 355, 2077; author reply 2078 | 4.0 | 1 |
| 12 | Rapid absorption and clinical effectiveness of intragastric mefloquine in the treatment of cerebral malaria in African children. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 44, 573-6 | 5.1 | 5 |
| 11 | Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy. <i>Journal of Infection</i> , 1999 , 39, 193-7 | 18.9 | 6 |
| 10 | Granulomatous inflammation and transmission of infectious disease. <i>Trends in Immunology</i> , 1999 , 20, 337-8 | | 1 |
| 9 | Molecular typing of Mycobacterium tuberculosis. <i>Lancet, The</i> , 1999 , 353, 1442 | 4.0 | 2 |
| 8 | Fatal primary multidrug-resistant tuberculosis in a heart transplant recipient. <i>Transplant International</i> , 1998 , 11, 305-7 | 3 | 14 |
| 7 | Highly active antiretroviral therapy. <i>Lancet, The</i> , 1998 , 351, 1056; author reply 1058-9 | 4.0 | 13 |
| 6 | Response of uncomplicated falciparum malaria to oral chloroquine and quinine in Burundi highlands. <i>Acta Tropica</i> , 1998 , 70, 25-33 | 3.2 | 7 |
| 5 | Tuberculosis among refugees and displaced people at the Burundi-Rwanda border. <i>Clinical Infectious Diseases</i> , 1998 , 26, 500-1 | 11.6 | 3 |
| 4 | Failure of prophylaxis against PCP in patients with HIV infection. <i>AIDS Patient Care and STDs</i> , 1998 , 12, 843-8 | 5.8 | 3 |
| 3 | Microsporidium species in pulmonary cavitary lesions of AIDS patients infected with <i>Rhodococcus equi</i> . <i>Clinical Infectious Diseases</i> , 1997 , 25, 926-7 | 11.6 | 9 |
| 2 | Fatal pneumothorax complicating BAL in a bone marrow transplant recipient with bronchiolitis obliterans. <i>Chest</i> , 1997 , 111, 1468-9 | 5.3 | 7 |
| 1 | The ParaSight-F rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of <i>Plasmodium falciparum</i> malaria. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997 , 91, 403-5 | 2 | 20 |